H Tanaka1. 1. Graduate school of biomedical science Ph.D. program, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8510, Japan. tanaka@cim.tmd.ac.jp
Abstract
OBJECTIVES: Recent important advances in the human genomics and post-genomic "omics" are now bringing about a new medical care which we call "omics-based medicine". In this article, we investigated the development and future possibilities of omics-based medicine. METHODS: We divided the development of omics-based medicine into three generations in order to clarify the main clinical goals and characteristics of informatics method of each generation, together with its future possibilities. RESULTS: The first generation of omics-based medicine started with "genomic medicine" based on the inborn individual differences of genome. It has opened the study of genetic polymorphism of the diseases and promoted the personalized medication based on the pharmacogenetic/pharmacogenomic difference of the drug response. In the second generation of omics-based medicine, owing to the advances in the high-throughput technology, vast amount of the various post-genomic disease omics data containing comprehensive molecular information of diseased somatic cells has become available. It reflects the ongoing state of diseases more closely and enables the predictive medicine such as prognosis prediction of disease by applying the data-driven analysis. Finally, due to the rapidly growing knowledge about the cellular molecular network, system-level understanding of the disease, called systems pathology, becomes possible. It can fully exploit the substantial contents of disease omics and will lead to a comprehensive understanding of disease process by using model-driven analysis. CONCLUSION: Omics-based medicine and systems pathology will realize a new personalized and predictive medicine.
OBJECTIVES: Recent important advances in the human genomics and post-genomic "omics" are now bringing about a new medical care which we call "omics-based medicine". In this article, we investigated the development and future possibilities of omics-based medicine. METHODS: We divided the development of omics-based medicine into three generations in order to clarify the main clinical goals and characteristics of informatics method of each generation, together with its future possibilities. RESULTS: The first generation of omics-based medicine started with "genomic medicine" based on the inborn individual differences of genome. It has opened the study of genetic polymorphism of the diseases and promoted the personalized medication based on the pharmacogenetic/pharmacogenomic difference of the drug response. In the second generation of omics-based medicine, owing to the advances in the high-throughput technology, vast amount of the various post-genomic disease omics data containing comprehensive molecular information of diseased somatic cells has become available. It reflects the ongoing state of diseases more closely and enables the predictive medicine such as prognosis prediction of disease by applying the data-driven analysis. Finally, due to the rapidly growing knowledge about the cellular molecular network, system-level understanding of the disease, called systems pathology, becomes possible. It can fully exploit the substantial contents of disease omics and will lead to a comprehensive understanding of disease process by using model-driven analysis. CONCLUSION: Omics-based medicine and systems pathology will realize a new personalized and predictive medicine.
Authors: Brodie A Parent; Max Seaton; Ravi F Sood; Haiwei Gu; Danijel Djukovic; Daniel Raftery; Grant E O'Keefe Journal: JAMA Surg Date: 2016-07-20 Impact factor: 14.766
Authors: Gregory S Ladics; Andrew Bartholomaeus; Phil Bregitzer; Nancy G Doerrer; Alan Gray; Thomas Holzhauser; Mark Jordan; Paul Keese; Esther Kok; Phil Macdonald; Wayne Parrott; Laura Privalle; Alan Raybould; Seung Yon Rhee; Elena Rice; Jörg Romeis; Justin Vaughn; Jean-Michel Wal; Kevin Glenn Journal: Transgenic Res Date: 2015-02-26 Impact factor: 2.788
Authors: Agnieszka Latosinska; Manousos Makridakis; Maria Frantzi; Daniel M Borràs; Bart Janssen; William Mullen; Jerome Zoidakis; Axel S Merseburger; Vera Jankowski; Harald Mischak; Antonia Vlahou Journal: Sci Rep Date: 2016-05-11 Impact factor: 4.379